Intarcia Gets Chance For AdComm Review Of ITCA 650; Hearing For Sotagliflozin Shot Down

 
• By Brenda Sandburg

FDA chief scientist encourages Intarcia to request advisory committee review of CDER’s proposal to refuse approval of its drug-device diabetes treatment. CDER again denies Lexicon request for hearing on proposal to deny approval of its SGLT2 inhibitor.

Microphone
FDA advisory committe may consider Intarcia's drug implant application for treatment of type 2 diabetes • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers